Regulation of Interleukin-6 Production by Prostaglandin E2 in Fetal Rat Osteoblasts: Role of Protein Kinase A Signaling Pathway

DOI PDF Web Site 4 Citations
  • Isabelle Millet
    Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, Connecticut, U.S.A.
  • Thomas L. Mccarthy
    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, U.S.A.
  • AgnÈS Vignery
    Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, U.S.A.

Search this article

Abstract

<jats:title>Abstract</jats:title> <jats:p>Prostaglandin E2 (PGE2) is an abundant eicosanoid in bone that has been implicated in a number of pathological states associated with bone loss. Interleukin-6 (IL-6) is a cytokine that plays a critical role in bone remodeling and appears to act as a downstream effector of most bone-resorbing agents. In light of the evidence that PGE2 induces IL-6 in the bone environment, this study was designed to investigate whether PGE2 regulated IL-6 expression by osteoblasts. Here we demonstrate that PGE2 is a potent inducer of IL-6 production by fetal rat osteoblasts and synergizes with lipopolysaccharide to enhance IL-6. We show that PGE2 stimulates the activity of the IL-6 promoter in osteoblasts, suggesting that PGE2 controls IL-6 gene expression at least at the transcriptional level. Moreover, we show that PGE2-mediated IL-6 induction is prevented by the cAMP antagonist, Rp-cAMP, and the protein kinase A (PKA) inhibitors, KT5720 and H89. Thus, our data indicate that PGE2 involves the cAMP–PKA signaling pathway to regulate IL-6 gene expression in osteoblasts.</jats:p>

Journal

Citations (4)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top